Topline results from the Phase 3 Essence-TIMI 73b study provide encouraging evidence of the efficacy of olezarsen in patients with moderate hypertriglyceridaemia (fasting TG 150 mg/dL to <500 mg/dL) with or at risk of atherosclerotic cardiovascular disease (ASCVD).
